-
1
-
-
85061633193
-
Cardiovascular protection with anti-hyperglycemic agents
-
[in press]
-
Deedwania P, Acharya T. Cardiovascular protection with anti-hyperglycemic agents. Am J Cardiovasc Drugs 2019; in press
-
(2019)
Am J Cardiovasc Drugs
, vol.19
, pp. 249-257
-
-
Deedwania, P.1
Acharya, T.2
-
2
-
-
85046132173
-
Economic costs of diabetes in the U.S. in 2017
-
American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care 2018;41:917-928.
-
(2018)
Diabetes Care
, vol.41
, pp. 917-928
-
-
American Diabetes Association1
-
3
-
-
85045767187
-
Global economic burden of diabetes in adults: projections from 2015 to 2030
-
Bommer C, Sagaova V, Heesemann E et al. Global economic burden of diabetes in adults: Projections from 2015 to 2030. Diabetes Care 2018;41:963-970.
-
(2018)
Diabetes Care
, vol.41
, pp. 963-970
-
-
Bommer, C.1
Sagaova, V.2
Heesemann, E.3
-
4
-
-
84879202874
-
Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association
-
Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: A policy statement from the American Heart Association. Circ Heart Fail 2013;6:606-619.
-
(2013)
Circ Heart Fail
, vol.6
, pp. 606-619
-
-
Heidenreich, P.A.1
Albert, N.M.2
Allen, L.A.3
-
5
-
-
85059500922
-
Heart failure in type 2 diabetes mellitus: impact of glucose-lowering agents, heart failure therapies, and novel therapeutic strategies
-
Kenny HC, Abel ED. Heart failure in type 2 diabetes mellitus: Impact of glucose-lowering agents, heart failure therapies, and novel therapeutic strategies. Circ Res 2019;124:121-141.
-
(2019)
Circ Res
, vol.124
, pp. 121-141
-
-
Kenny, H.C.1
Abel, E.D.2
-
7
-
-
84981201088
-
Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014
-
Afkarian M, ZelnickLR, Hall YN et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA 2016;316:602-610.
-
(2016)
JAMA
, vol.316
, pp. 602-610
-
-
Afkarian, M.1
Zelnick, L.R.2
Hall, Y.N.3
-
8
-
-
0037108454
-
Age and the burden of death attributable to diabetes in the United States
-
Saydah SH, Eberhardt MS, Loria CM et al. Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol 2002;156:714-719.
-
(2002)
Am J Epidemiol
, vol.156
, pp. 714-719
-
-
Saydah, S.H.1
Eberhardt, M.S.2
Loria, C.M.3
-
9
-
-
85047497547
-
Risk of incident heart failure in patients with diabetes and asymptomatic left ventricular systolic dysfunction
-
Rorth R, Jhundi PS, Mogensen UM et al. Risk of incident heart failure in patients with diabetes and asymptomatic left ventricular systolic dysfunction. Diabetes Care 2018;41:1285-1291.
-
(2018)
Diabetes Care
, vol.41
, pp. 1285-1291
-
-
Rorth, R.1
Jhundi, P.S.2
Mogensen, U.M.3
-
10
-
-
85046398177
-
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology
-
Seferovic PM, Petrie MC, Filippatos GS et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J. Heart Fail 2018;20:853-872.
-
(2018)
Eur J Heart Fail
, vol.20
, pp. 853-872
-
-
Seferovic, P.M.1
Petrie, M.C.2
Filippatos, G.S.3
-
11
-
-
85062154232
-
Heart disease and stroke statistics – 2019 update: a report from the American Heart Association
-
Benjamin EJ, Muntner P, Alonso A et al. Heart disease and stroke statistics – 2019 update: A report from the American Heart Association. Circulation 2019;139:e56-e528.
-
(2019)
Circulation
, vol.139
, pp. e56-e528
-
-
Benjamin, E.J.1
Muntner, P.2
Alonso, A.3
-
12
-
-
84988458382
-
Temporal trends and factors associated with diabetes mellitus among patient hospitalized with heart failure: findings from get with the guidelines – heart failure registry
-
Echouffo-Tcheugui JB, Xu H, DeVore AD et al. Temporal trends and factors associated with diabetes mellitus among patient hospitalized with heart failure: Findings from Get With the Guidelines – Heart Failure registry. Am Heart J 2016;182:9-20.
-
(2016)
Am Heart J
, vol.182
, pp. 9-20
-
-
Echouffo-Tcheugui, J.B.1
Xu, H.2
DeVore, A.D.3
-
13
-
-
0037356757
-
Higher incidence of new-onset diabetes in patients with heart failure
-
Grundy SM. Higher incidence of new-onset diabetes in patients with heart failure. Am J Med 2003;114:331-332.
-
(2003)
Am J Med
, vol.114
, pp. 331-332
-
-
Grundy, S.M.1
-
14
-
-
0037353460
-
Functional class in patients with heart failure is associated with the development of diabetes
-
Tenenbaum A, Motro M, Fishman EZ et al. Functional class in patients with heart failure is associated with the development of diabetes. Am J Med 2003;114:271-275.
-
(2003)
Am J Med
, vol.114
, pp. 271-275
-
-
Tenenbaum, A.1
Motro, M.2
Fishman, E.Z.3
-
15
-
-
79551494642
-
Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices
-
Uriel N, Naka Y, Colombo PC et al. Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices. Eur J Heart Fail 2011;13:195-199.
-
(2011)
Eur J Heart Fail
, vol.13
, pp. 195-199
-
-
Uriel, N.1
Naka, Y.2
Colombo, P.C.3
-
16
-
-
85064646839
-
Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies
-
Rangaswami J, Bhalla V, Blair JEA et al. Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies. Circulation 2019;139:e840-878.
-
(2019)
Circulation
, vol.139
, pp. e840-e878
-
-
Rangaswami, J.1
Bhalla, V.2
Blair, J.E.A.3
-
17
-
-
85056655699
-
Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association – European Society of Cardiology
-
Maack C, Lehrke M, Backs J et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association – European Society of Cardiology. Eur Heart J 2018;39:4243-4254.
-
(2018)
Eur Heart J
, vol.39
, pp. 4243-4254
-
-
Maack, C.1
Lehrke, M.2
Backs, J.3
-
18
-
-
84872532310
-
Association between glycated haemoglobin and the risk of congestive heart failure in diabetes mellitus: systematic review and meta analysis
-
Ergou S, et al. Association between glycated haemoglobin and the risk of congestive heart failure in diabetes mellitus: systematic review and meta analysis. Eur J Heart Fail. 2013;15:185-193.
-
(2013)
Eur J Heart Fail
, vol.15
, pp. 185-193
-
-
Ergou, S.1
-
19
-
-
0034641568
-
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (ukpds 35): prospective observational study
-
Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (ukpds 35): Prospective observational study. BMJ 2000;321:405-412.
-
(2000)
BMJ
, vol.321
, pp. 405-412
-
-
Stratton, I.M.1
Adler, A.I.2
Neil, H.A.3
-
20
-
-
85132189046
-
Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss
-
Lee R, Wong TY, Sabanayagam C et al. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye and Vision 2015;2:17
-
(2015)
Eye and Vision
, vol.2
, pp. 17
-
-
Lee, R.1
Wong, T.Y.2
Sabanayagam, C.3
-
21
-
-
85038937860
-
The prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction
-
Sandesara PB, O'’Neal WT, Kelli HM et al. The prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction. Diabetes Care 2018;41:150-155.
-
(2018)
Diabetes Care
, vol.41
, pp. 150-155
-
-
Sandesara, P.B.1
O'Neal, W.T.2
Kelli, H.M.3
-
22
-
-
85065843781
-
Influence of microvascular disease on cardiovascular events in type 2 diabetes
-
Verma S, Wanner C, Zweiner I et al. Influence of microvascular disease on cardiovascular events in type 2 diabetes. J Am Coll Cardiol 2019;73:2780-2782.
-
(2019)
J Am Coll Cardiol
, vol.73
, pp. 2780-2782
-
-
Verma, S.1
Wanner, C.2
Zweiner, I.3
-
24
-
-
84896092380
-
Molecular mechanisms of diabetic cardiomyopathy
-
Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014;57:660-671.
-
(2014)
Diabetologia
, vol.57
, pp. 660-671
-
-
Bugger, H.1
Abel, E.D.2
-
25
-
-
85019634930
-
An overview of the inflammatory signaling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy
-
Frati, G. An overview of the inflammatory signaling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy. Cardiovascular Res. 2017; 113:378-388.
-
(2017)
Cardiovasc Res
, vol.113
, pp. 378-388
-
-
Frati, G.1
-
26
-
-
44949172981
-
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme
-
MacDonald MR, Petrie MC, Varyani F et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008;29:1377-1385.
-
(2008)
Eur Heart J
, vol.29
, pp. 1377-1385
-
-
MacDonald, M.R.1
Petrie, M.C.2
Varyani, F.3
-
27
-
-
0034739458
-
Coronary composition and macrophage infiltration in atherectomy specimens from patient with diabetes mellitus
-
Moreno PR, Murcia AM, Palacios IF et al. Coronary composition and macrophage infiltration in atherectomy specimens from patient with diabetes mellitus. Circulation 2000;102:2180-2184.
-
(2000)
Circulation
, vol.102
, pp. 2180-2184
-
-
Moreno, P.R.1
Murcia, A.M.2
Palacios, I.F.3
-
28
-
-
49649090453
-
Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome
-
Undas A, Wiek I, Stepien E, Zmudka K, Tracz W. Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome. Diabetes Care. 2008;31:1590-1595.
-
(2008)
Diabetes Care
, vol.31
, pp. 1590-1595
-
-
Undas, A.1
Wiek, I.2
Stepien, E.3
Zmudka, K.4
Tracz, W.5
-
31
-
-
84937227669
-
Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes
-
Seferovic PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015;36:1718-1727.
-
(2015)
Eur Heart J
, vol.36
, pp. 1718-1727
-
-
Seferovic, P.M.1
Paulus, W.J.2
-
32
-
-
85064836178
-
Diabetic cardiomyopathy: what is it and can it be fixed?
-
Dillmann WH. Diabetic cardiomyopathy: What is it and can it be fixed? Circ Res 2019;124:1160-1162.
-
(2019)
Circ Res
, vol.124
, pp. 1160-1162
-
-
Dillmann, W.H.1
-
33
-
-
0015498586
-
New type of cardiomyopathy associated with diabetic glomerulosclerosis
-
Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972;30:595-602.
-
(1972)
Am J Cardiol
, vol.30
, pp. 595-602
-
-
Rubler, S.1
Dlugash, J.2
Yuceoglu, Y.Z.3
-
34
-
-
84873359828
-
Kidney disease and increased mortality risk in type 2 diabetes
-
Afkarian M, Sachs MC, Kestenbaum B et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013;24:302-308.
-
(2013)
J Am Soc Nephrol
, vol.24
, pp. 302-308
-
-
Afkarian, M.1
Sachs, M.C.2
Kestenbaum, B.3
-
35
-
-
85049363563
-
Pathology identifies glomerular treatment targets in diabetic nephropathy
-
Alpers CE, Hudkins KL. Pathology identifies glomerular treatment targets in diabetic nephropathy. Kidney Res Clin Pract 2018;37:106-111.
-
(2018)
Kidney Res Clin Pract
, vol.37
, pp. 106-111
-
-
Alpers, C.E.1
Hudkins, K.L.2
-
36
-
-
85064005750
-
Consequences of glomerular hyperfiltration: the role of physical forces in the pathogenesis of chronic kidney disease in diabetes and obesity
-
[epublished April 4]
-
Chagnac A, Zingerman B, Rozen-Zvi B, Herman-Edelstein M. Consequences of glomerular hyperfiltration: The role of physical forces in the pathogenesis of chronic kidney disease in diabetes and obesity. Nephron 2019; epublished April 4
-
(2019)
Nephron
-
-
Chagnac, A.1
Zingerman, B.2
Rozen-Zvi, B.3
Herman-Edelstein, M.4
-
37
-
-
84928743782
-
Uric acid as a biomarker and a therapeutic target in diabetes
-
Lytvyn Y, Perkins BA, Cherney DZI. Uric acid as a biomarker and a therapeutic target in diabetes. Can J Diabetes 2015;39:239-246.
-
(2015)
Can J Diabetes
, vol.39
, pp. 239-246
-
-
Lytvyn, Y.1
Perkins, B.A.2
Cherney, D.Z.I.3
-
38
-
-
0032511583
-
Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
-
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998;352:837-853.
-
(1998)
Lancet
, vol.352
, pp. 837-853
-
-
UK Prospective Diabetes Study (UKPDS) Group1
-
39
-
-
0034641550
-
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study
-
Adler AI, Stratton IM, Yudkin JS et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-419.
-
(2000)
BMJ
, vol.321
, pp. 412-419
-
-
Adler, A.I.1
Stratton, I.M.2
Yudkin, J.S.3
-
40
-
-
85017341929
-
Evolocumab and clinical outcomes in patients with cardiovascular disease
-
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-1722.
-
(2017)
N Engl J Med
, vol.376
, pp. 1713-1722
-
-
Sabatine, M.S.1
Giugliano, R.P.2
Keech, A.C.3
-
41
-
-
84907087561
-
Angiotensin-neprilysin inhibition versus enalapril in heart failure
-
McMurray JJ, Packer M, Desai AS et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004.
-
(2014)
N Engl J Med
, vol.371
, pp. 993-1004
-
-
McMurray, J.J.1
Packer, M.2
Desai, A.S.3
-
42
-
-
85061124164
-
Angiotensin-neprilysin inhibition in acute decompensated heart failure
-
Velazquez EJ, Morrow DA, DeVore AD et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019;380:539-548.
-
(2019)
N Engl J Med
, vol.380
, pp. 539-548
-
-
Velazquez, E.J.1
Morrow, D.A.2
DeVore, A.D.3
-
43
-
-
85060260357
-
Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease
-
Alcic RZ, Neumiller JJ, Johnson EJ et al. Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease. Diabetes 2019;68:248-257.
-
(2019)
Diabetes
, vol.68
, pp. 248-257
-
-
Alcic, R.Z.1
Neumiller, J.J.2
Johnson, E.J.3
-
44
-
-
85058733652
-
Standards of medical Care in Diabetes – 2019
-
Summary of revisions: Standards of Medical Care in Diabetes – 2019. Diabetes Care 2019;42(Suppl 1):S4-S6.
-
(2019)
Diabetes Care
, vol.42
, pp. S4-S6
-
-
Summary of revisions1
|